Skip to search formSkip to main contentSkip to account menu

yttrium-90-ibritumomab tiuxetan

Known as: yttrium Y90 ibritumomab tiuxetan, Y90-labeled ibritumomab tiuxetan, Yttrium Y 90 Ibritumomab Tiuxetan 
A radiolabeled monoclonal antibody that is used to treat certain types of B-cell non-Hodgkin lymphoma and is being studied in the treatment of other… 
National Institutes of Health

Related topics

Related topics

13 relations
Free Radical FormationHuman B-Lymphocyte Antigen CD20, humanIDEC-In2B8/rituximab/yttrium Y 90 ibritumomab tiuxetanIbritumomab (In2B8/Y2B8 Radiolabeling Kit)

Narrower (2)

IDEC-Y2B8Zevalin

Broader (2)

Monoclonal Antibodiesibritumomab tiuxetan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Exposure to ibritumomab tiuxetan and incidence of treatment-related myeloid neoplasms among older patients with B-cell lymphoma: a population-based study
Background: Ibritumomab tiuxetan (IbT) is a radioimmunoconjugate linking rituximab with 90Y isotope. IbT is approved for… 
2019
2019
90Y‐IBRITUMOMAB TIUXETAN IN PATIENTS WITH EXTRA‐NODAL MARGINAL ZONE B‐CELL LYMPHOMA OF MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT LYMPHOMA) – THE ZENO STUDY
Patients with gastric MALT lymphoma responding to initial HPeradication have an excellent outcome, and no further oncological… 
2013
2013
The Preclinical and Clinical Evaluation of VB 6-845 : An Immunotoxin with a De-Immunized Payload for the Systemic Treatment of Solid Tumors
One of the challenges in cancer therapy is to eradicate tumor cells while minimizing the toxic side effects to normal tissue that… 
Review
2011
Review
2011
The double flap partial reconstruction technique for the avulsion-type finger injuries: a case report
unknown. We conducted a PubMed review of article titles and available abstracts and returned in excess of 70 reported cases of… 
2010
2010
Yttrium microspheres with cetuximab plus irinotecan for patients with advanced colorectal cancer metastases to liver.
TPS197 Background: Unresectable colorectal cancerhepatic metastases (CRCHM) are a major cause of morbidity and mortality… 
2006
2006
90Y-Ibritumomab tiuxetan: new drug, interesting concept, and encouraging in practice.
2006
2006
Ibritumomab Tiuxetan (Zevalin) Followed by High-Dose Chemotherapy and Autologous Stem-Cell Transplantation Results in Improved Survival of Patients with Chemo-Refractory Non-Hodgkin’s Lymphoma…
High-dose chemotherapy and autologous stem-cell transplantation (autoSCT) have an established therapeutic role in patients (pts… 
2005
2005
Yttrium-90 ibritumomab tiuxetan (zevalin) induces high response rates in previously treated patients with diffuse large B cell lymphoma (DLBCL)
2004
2004
Metastatic Breast Cancer in a 54-Year-Old Woman: Integrative Treatment with Yttrium-90 Radioembolization
In 1993, a 54-year-old woman was diagnosed with early-stage breast adenocarcinoma and treated with doxorubicin and… 
1990
1990
[The treatment of gonarthritis with yttrium-90].
200 patients with gonarthritis--142 patients with rheumatoid arthritis, 38 patients with psoriatic arthritis, 7 patients with…